Resources
93 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 5/31/2024
The American Medical Association's (AMA) Telehealth Implementation Playbook provides information on digital health implementation.
Posted 4/26/2024
The Nitazenes Overview resource created by RCORP-TA describes what nitazenes are, how to determine if they are in your community, and how to prevent and respond to overdoses due to nitazenes. Additional resources are also provided to learn more about nitazenes.
Posted 4/19/2024
April is Alcohol Awareness Month. This month offers a time to raise awareness and understanding of alcohol use and misuse. Resources and support is available for individuals struggling with alcohol use. In addition, the Substance Abuse and Mental Health Services Administration provides a social media toolkit for communities to utilize.
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.
Posted 3/29/2024
A planning committee of the National Academies of Sciences, Engineering, and Medicine organized and conducted a two-day virtual public workshop that brought together data experts, program implementers and evaluators, and other key interested parties to explore data collection efforts, evidence gaps, and research needs on harm reduction for people who use drugs (PWUD).
Posted 12/15/2023 (updated 3/28/2024)
The Opioid-Overdose Reduction Continuum of Care Approach is a guide for policymakers for implementing evidence-based strategies that address opioid overdose.
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 9/29/2023 (updated 3/27/2024)
The 2023 RCORP-Overdose Response Onboarding Packet contains strategies and resources to assist grantees in the implementation of your new Overdose Response (OR) grant. The Onboarding Packet includes tools to support grant-funded activities, along with information on accessing TA.
Posted 8/22/2023 (updated 3/26/2024)
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.